These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35150319)

  • 21. A stronger antibody response in increased disease severity of SARS-CoV-2.
    de Oliveira MI; Aciole MR; Neves PAF; Silva VPOE; Silva MPOE; de Lorena VMB; de Araújo PSR
    BMC Infect Dis; 2024 Jan; 24(1):17. PubMed ID: 38166763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays.
    Qian C; Zhou M; Cheng F; Lin X; Gong Y; Xie X; Li P; Li Z; Zhang P; Liu Z; Hu F; Wang Y; Li Q; Zhu Y; Duan G; Xing Y; Song H; Xu W; Liu BF; Xia F
    Clin Chem Lab Med; 2020 Aug; 58(9):1601-1607. PubMed ID: 32609640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duration of antibody responses following severe acute respiratory syndrome coronavirus 2 infection.
    Jiang Y; Wei X; Wang H; Li G
    Ir J Med Sci; 2022 Dec; 191(6):2677-2680. PubMed ID: 34982375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design.
    Scheiblauer H; Nübling CM; Wolf T; Khodamoradi Y; Bellinghausen C; Sonntagbauer M; Esser-Nobis K; Filomena A; Mahler V; Maier TJ; Stephan C
    J Clin Virol; 2022 Jan; 146():105052. PubMed ID: 34920374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays.
    Harley K; Gunsolus IL
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33106364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a Lateral Flow Immunoassay COVIDTECH
    Exinger J; Hartard C; Lafferrière F; Fenninger C; Charbonnière LJ; Jeulin H
    Jpn J Infect Dis; 2022 Jul; 75(4):334-340. PubMed ID: 34980703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course.
    Higgins V; Fabros A; Wang XY; Bhandari M; Daghfal DJ; Kulasingam V
    Clin Biochem; 2021 Apr; 90():1-7. PubMed ID: 33476578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories.
    Harritshøj LH; Gybel-Brask M; Afzal S; Kamstrup PR; Jørgensen CS; Thomsen MK; Hilsted L; Friis-Hansen L; Szecsi PB; Pedersen L; Nielsen L; Hansen CB; Garred P; Korsholm TL; Mikkelsen S; Nielsen KO; Møller BK; Hansen AT; Iversen KK; Nielsen PB; Hasselbalch RB; Fogh K; Norsk JB; Kristensen JH; Schønning K; Kirkby NS; Nielsen ACY; Landsy LH; Loftager M; Holm DK; Nilsson AC; Sækmose SG; Grum-Schwensen B; Aagaard B; Jensen TG; Nielsen DM; Ullum H; Dessau RB
    J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33574119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.
    Servian CDP; Spadafora-Ferreira M; Dos Anjos DCC; Guilarde AO; Gomes-Junior AR; Borges MASB; Masson LC; Silva JMM; de Lima MHA; Moraes BGN; Souza SM; Xavier LE; de Oliveira DCA; Batalha-Carvalho JV; Moro AM; Bocca AL; Pfrimer IAH; Costa NL; Feres VCR; Fiaccadori FS; Souza M; Gardinassi LG; Durigon EL; Romão PRT; Jorge SAC; Coelho V; Botosso VF; Fonseca SG
    Front Immunol; 2023; 14():1206979. PubMed ID: 37876932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients.
    Zeng F; Wu M; Wang J; Li J; Hu G; Wang L
    J Med Virol; 2021 Dec; 93(12):6506-6511. PubMed ID: 34170519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG.
    Gambino CM; Lo Sasso B; Colomba C; Giglio RV; Agnello L; Bivona G; Ciaccio M
    Biochem Med (Zagreb); 2020 Oct; 30(3):030901. PubMed ID: 33071558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study.
    Moradi G; Mohamadi Bolbanabad A; Ahmadi S; Aghaei A; Bahrami F; Veysi A; Nasiri Kalmarzi R; Shokri A; Ghaderi E; Mohsenpour B; Mohammadi A
    Int Immunopharmacol; 2021 Sep; 98():107893. PubMed ID: 34174700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
    Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
    J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
    Al-Mughales JA; Al-Mughales TJ; Saadah OI
    Front Immunol; 2021; 12():705441. PubMed ID: 34539635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: A retrospective study in outbreak on a cruise ship.
    Kaku N; Nishimura F; Shigeishi Y; Tachiki R; Sakai H; Sasaki D; Ota K; Sakamoto K; Kosai K; Hasegawa H; Izumikawa K; Ariyoshi K; Mukae H; Yasuda J; Morita K; Kohno S; Yanagihara K
    PLoS One; 2021; 16(9):e0257452. PubMed ID: 34582459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A follow up study of total IgM, IgG, nucleoprotein and spike protein antibodies against severe acute respiratory syndrome (SARS) coronavirus in patients with SARS].
    Yan HP; Tan YF; Zhuang H; Zhou YS; Zhao CH; Feng X; Jin RH; Wu H; Fu Y
    Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):896-9. PubMed ID: 17313874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
    Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
    Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiplex Antibody Analysis of IgM, IgA and IgG to SARS-CoV-2 in Saliva and Serum From Infected Children and Their Close Contacts.
    Dobaño C; Alonso S; Vidal M; Jiménez A; Rubio R; Santano R; Barrios D; Pons Tomas G; Melé Casas M; Hernández García M; Girona-Alarcón M; Puyol L; Baro B; Millat-Martínez P; Ajanovic S; Balanza N; Arias S; Rodrigo Melero N; Carolis C; García-Miquel A; Bonet-Carné E; Claverol J; Cubells M; Fortuny C; Fumadó V; Codina A; Bassat Q; Muñoz-Almagro C; Fernández de Sevilla M; Gratacós E; Izquierdo L; García-García JJ; Aguilar R; Jordan I; Moncunill G
    Front Immunol; 2022; 13():751705. PubMed ID: 35154094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19.
    Glück V; Grobecker S; Tydykov L; Salzberger B; Glück T; Weidlich T; Bertok M; Gottwald C; Wenzel JJ; Gessner A; Schmidt B; Peterhoff D
    Infection; 2021 Aug; 49(4):739-746. PubMed ID: 33689159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.